Breaking News
April 22, 2019 - The U.S government may account for up to $37.8 billion due to opioid epidemic
April 22, 2019 - Improving ACA’s Insurance Coverage Provisions will lead to better care for patients
April 22, 2019 - Study identifies possible therapeutic effects of curcumin on stomach cancer
April 22, 2019 - Hyaline fibromatosis syndrome – Genetics Home Reference
April 22, 2019 - Scientists use CRISPR for possible ‘bubble boy’ therapy
April 22, 2019 - Hematologist (and a mom, singer, actress and much more) stands up for diversity
April 22, 2019 - Novel AI voice tool can help diagnose PTSD
April 22, 2019 - Overlooked part of cell’s internal machinery may hold key to treating acute myeloid leukemia
April 22, 2019 - MIT scientists reverse some behavioral symptoms of rare neurodevelopmental disorder
April 22, 2019 - Scientists find new therapy target for drug-induced liver failure
April 22, 2019 - Opioid dose variability could lead to increased risk of overdose, study suggests
April 22, 2019 - Newly developed model predicts salmonella outbreaks several months in advance
April 22, 2019 - Deep-learning model better predicts survival outcomes for lung cancer
April 22, 2019 - One in Three U.S. Adults Aged 35 to 44 May Have Drinking Problem
April 22, 2019 - Why the measles virus is so contagious
April 22, 2019 - Magnet ‘Zap’ to the Brain Might Jumpstart Aging Memory
April 22, 2019 - Immune response to gut microbes may be early indicator of type 1 diabetes
April 22, 2019 - Destination Limbo: Health Suffers Among Asylum Seekers In Crowded Border Shelter
April 22, 2019 - Research shows how dopamine contributes to sex differences in worms
April 22, 2019 - Marijuana users weigh less compared to non-users
April 22, 2019 - Research uncovers critical RNA processing aberrations in ALS and FTD
April 22, 2019 - Many cancer patients use marijuana and prescription opioids, study reveals
April 22, 2019 - Frailty may up fracture risk in patients with type 2 diabetes
April 22, 2019 - Study provides new insight into how obesity, insulin resistance can affect cognition
April 22, 2019 - Study seeks to better understand the genetic causes for hypospadias
April 22, 2019 - FDA grants approval of first generic naloxone nasal spray to treat opioid overdose
April 22, 2019 - FDA authorizes marketing of first medical device to treat ADHD
April 22, 2019 - Vanderbilt researchers to develop and test ‘safe harbor’ standards of care
April 22, 2019 - You’re probably brushing your teeth wrong – here are four tips for better dental health
April 22, 2019 - Pharmacy closures contribute to medication non-adherence among heart patients
April 22, 2019 - Using Edge AI technology to observe behavior of cattle
April 22, 2019 - Bacteria play a role in the development of stomach ulcers in pigs
April 22, 2019 - Hand Hygiene Compliance Poor in Task Transitions
April 22, 2019 - smoking could harm your baby
April 22, 2019 - Scientists identify rare, paradoxical response to antiretroviral therapy
April 21, 2019 - More TV, Tablets, More Attention Issues at Age 5
April 21, 2019 - Drug reduces risk of kidney failure in people with diabetes, study finds
April 21, 2019 - New research identifies novel link between antibiotic resistance and climate change
April 21, 2019 - Simple intervention can provide lasting protection for teens against junk food marketing
April 21, 2019 - The protein p38-gamma identified as a new therapeutic target in liver cancer
April 21, 2019 - Novel system enables researchers to study bacteria within mini-tissues in a dish
April 21, 2019 - Discovery of oral cancer biomarkers could save thousands of lives
April 21, 2019 - Geneva Exhibition committee gives gold medals to two medications developed by Kazan
April 21, 2019 - Scientists aim to minimize or eliminate hair loss during cancer treatment
April 21, 2019 - WiFi interacts with signaling pathways in the human brain
April 21, 2019 - Stroke Hospitalizations Down in Black, White Medicare Enrollees
April 21, 2019 - First common risk genes discovered for autism
April 21, 2019 - Researchers map auditory sensory system of the mouse brain
April 21, 2019 - Scientists Bring Pig’s Brain, Dead 4 Hours, Back to ‘Cellular Activity’
April 21, 2019 - Virtual reality a promising tool for reducing fears and phobia in autism
April 21, 2019 - New analysis lists out opportunities for U.S. medical schools to advance population health
April 21, 2019 - More sleep may help teens with ADHD focus and organize
April 21, 2019 - Breakthrough antibody treatment suppresses HIV without antivirals
April 21, 2019 - AveXis Data Reinforce Effectiveness of Zolgensma in Treating Spinal Muscular Atrophy (SMA) Type 1
April 21, 2019 - Is your hand pain arthritis, carpal tunnel or something else?
April 21, 2019 - Measles outbreaks may become more frequent if vaccination rates continue to decline
April 21, 2019 - Researchers succeed in accelerating process of creating 3D images
April 21, 2019 - Tiny worm mimics key genetic risk for Alzheimer’s
April 21, 2019 - Angry dreams explained by brain waves
April 20, 2019 - Parenteral Antimicrobial Tx at Home Burdens Children’s Caregivers
April 20, 2019 - Diabetes treatment may keep dementia, Alzheimer’s at bay
April 20, 2019 - New bandage-like biosensor collects and analyzes sweat
April 20, 2019 - A comprehensive, centralized database of bovine milk compounds
April 20, 2019 - Two new epigenetic regulators maintain self-renewal of embryonic stem cells
April 20, 2019 - New Evidence That Veggies Beat Steak for Heart Health
April 20, 2019 - Study reveals genes associated with heavy drinking and alcoholism
April 20, 2019 - Texas A&M AgriLife becomes the newest member of NutriRECS international consortium
April 20, 2019 - In most states, insurance won’t cover addiction treatments
April 20, 2019 - Computer-based memory games may be beneficial for individuals with fragile X syndrome
April 20, 2019 - Timing of food intake influences molecular clock in the liver of mice
April 20, 2019 - Precise decoding of breast cancer cells paves way for new treatment option
April 20, 2019 - Scientists use 3D imaging to help model complex processes performed by placenta
April 20, 2019 - MediciNova Announces Plans to Move Forward with a Phase 3 Trial of MN-166 (ibudilast) in ALS
April 20, 2019 - Genetic variants that protect against obesity could aid new weight loss medicines
April 20, 2019 - New technology developed for microscopic imaging in living organisms
April 20, 2019 - when quitting cigarettes, consider using more nicotine, not less
April 20, 2019 - Key proteins can block Listeria without triggering the death of host cells
April 20, 2019 - Researchers create a working model of cerebral tract to study brain function
April 20, 2019 - New study shows that microbes can help break toxic chemical in dust
April 20, 2019 - Scientists use NIR light and injected DNA nanodevice to guide stem cells to injury
First Human Study of “Robotic” RaniPill™ Capsule to Replace Injections Announced by Rani Therapeutics

First Human Study of “Robotic” RaniPill™ Capsule to Replace Injections Announced by Rani Therapeutics

image_pdfDownload PDFimage_print

SAN JOSE, Calif., Feb. 28, 2019 /PRNewswire/ — The first human study of a pill designed to replace injections of biologics is today being announced by Rani Therapeutics, the inventor of the RaniPill™ capsule. The human study follows more than 100 animal studies testing the RaniPill capsule’s delivery of drugs such as insulin and Humira into the wall of the small intestine, where Rani has demonstrated 100% equivalence with injections.

The human study was conducted at a Clinical Research Organization (CRO) in Texas, under the Investigational Review Board (IRB) approval.  There were two sub-groups, one cohort was fed and another fasted.  Each subject swallowed a drug-free version of the RaniPill capsule.  The study, which evaluated the RaniPill capsule platform, focused on safety and tolerability.

The results revealed no sensation of the capsule inflating or deploying, and the successful passing of the remnants. The RaniPill capsule was well-tolerated by both male and female adult subjects of similar BMI with no adverse events.  The study showed similar intestinal deployment times for both fasted and fed subjects, indicating that food does not impact the RaniPill capsule’s performance.  The next human study will be conducted later this year and will include a drug-filled resorbable needle.

This human study builds on Rani’s extensive preclinical porcine and canine studies conducted over five years with 10 molecules, including antibodies, peptides, and proteins.  These studies in large animal models have demonstrated delivery equivalent to 3 milligrams (mg) or 3,000 micrograms (μg) of drug and bioavailability that is on par or better than subcutaneous injections.  For context, 3,000 μg translates into 80 units of insulin.  This dosage covers not only the pre-diabetic patient (300 micrograms) but also patients with more severe chronic diabetes conditions.

“This is a first-of-its-kind innovation that combines a range of disciplines from engineering, chemistry and materials science to anatomy, physiology, and biochemistry to convert injectable drugs into pills,” said Mir Imran, Rani’s Chairman and CEO.  “The safety and tolerability of the RaniPill capsule in this first human study give us confidence in our platform as we prepare for human testing of the RaniPill capsule with Octreotide (a drug for the treatment of acromegaly) in the coming months.”

Rani’s extensive intellectual property portfolio, which includes over 150 patent applications filed and more than 50 patents issued in the U.S., covers important innovations for injecting into the gastrointestinal tract including the stomach and intestines.

Dennis Ausiello, M.D., Physician-in-Chief, Emeritus at Massachusetts General Hospital and Jackson Distinguished Professor of Clinical Medicine at Harvard Medical School and Rani board member added, “The oral delivery of biologics is considered the holy grail of drug delivery.  Rani has generated impressive bioavailability data in preclinical testing, while methodically and significantly de-risking its platform.  With strong preclinical results and an extensive patent portfolio, Rani is poised to benefit patients across a range of therapeutic areas, including diabetes, psoriasis, Crohn’s disease, rheumatoid arthritis, hemophilia, among others.”

About the RaniPill capsule

The RaniPill capsule has a special enteric coating that protects itself in the acidic environment of the stomach.  When the capsule moves into the intestine and pH levels rise, the enteric coating dissolves and a chemical reaction takes place which inflates a balloon. The pressure in the balloon pushes the dissolvable microneedle filled with the drug into the intestinal wall.  The uptake of the drug is immediate due to the highly vascularized intestinal wall.  Because there are no sharp pain receptors in the intestine, the injection is painless.  By comparison, subcutaneous injections can be painful, especially when patients have to inject themselves chronically.

The RaniPill capsule uses no metal, springs or other elements that the body cannot easily absorb or pass quickly. The company’s more than 100 preclinical studies, including the testing of more than 1,000 capsules in animal models, and its recent human study, have shown that large animals and humans are able to pass the remnants of the RaniPill capsule within 1-4 days.

About Rani Therapeutics

Rani Therapeutics has developed a robotic pill that is designed to replace injections of large drug molecules including peptides, proteins, and antibodies.  Rani has raised over $142 million in funding from GV, the investment arm of Alphabet Inc., and other major venture investors, and has partnered with Novartis and Shire Pharmaceuticals, among others.

The research and technology behind Rani Therapeutics came out of InCube Labs, a multi-disciplinary life sciences R&D lab focused on breakthrough medical innovations. InCube is led by Mir Imran, a prolific medical inventor, entrepreneur, and investor. Mir has founded more than 20 life sciences companies and holds more than 400 issued and pending patents in the U.S.  Mir has dedicated his 40+ year career to creating and commercializing innovations that have a profound impact on the lives of millions of patients.  For more information, please visit www.ranitherapeutics.com.

SOURCE Rani Therapeutics

Posted: February 2019

Tagged with:

About author

Related Articles